Cargando…

Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18–50 Years and RSV-Seropositive Children 12–24 Months

BACKGROUND: Respiratory syncytial virus (RSV) remains a leading cause of pediatric morbidity, with no approved vaccine. We assessed the safety and immunogenicity of the Ad26.RSV.preF vaccine candidate in adults and children. METHODS: In this randomized, double-blind, phase 1/2a, placebo-controlled s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stuart, Arabella S V, Virta, Miia, Williams, Kristi, Seppa, Ilkka, Hartvickson, Robyn, Greenland, Melanie, Omoruyi, Edmund, Bastian, Arangassery Rosemary, Haazen, Wouter, Salisch, Nadine, Gymnopoulou, Efi, Callendret, Benoit, Faust, Saul N, Snape, Matthew D, Heijnen, Esther
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796164/ https://www.ncbi.nlm.nih.gov/pubmed/36259542 http://dx.doi.org/10.1093/infdis/jiac407

Ejemplares similares

902. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of a Single Immunization of Ad26.RSV.preF against RSV Infection in a Viral Challenge Model in Healthy Adults
por: DeVincenzo, John, et al.
Publicado: (2019)

RSV A2-Based Prefusion F Vaccine Candidates Induce RSV A and RSV B Cross Binding and Neutralizing Antibodies and Provide Protection against RSV A and RSV B Challenge in Preclinical Models
por: Cox, Freek, et al.
Publicado: (2023)

Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study
por: Sadoff, Jerald, et al.
Publicado: (2021)

Phase 2b Study of an Ad26.RSV.preF Vaccine for Prevention of RSV-mediated Respiratory Tract Disease in Older Adults
por: Falsey, Ann, et al.
Publicado: (2021)

LB14. Efficacy and Immunogenicity of an Ad26.RSV.preF-based Vaccine in the Prevention of RT-PCR-confirmed RSV-mediated Lower Respiratory Tract Disease in Adults Aged ≥65 Years: A Randomized, Placebo-controlled, Phase 2b Study
por: Falsey, Ann R, et al.
Publicado: (2021)

2321. Long-term immunogenicity of Ad26.RSV.preF/RSV preF protein vaccine against RSV in a phase 2b study by age and risk level
por: Comeaux, Christy A, et al.
Publicado: (2022)

2775. Safety and Immunogenicity of a Seasonal Influenza Vaccine and Ad26.RSV.preF Vaccine With and Without Co-Administration: A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study in Adults Aged ≥ 60 Years
por: Comeaux, Christy, et al.
Publicado: (2019)

Transient opening of trimeric prefusion RSV F proteins
por: Gilman, Morgan S. A., et al.
Publicado: (2019)

Adjuvant Selection for Influenza and RSV Prefusion Subunit Vaccines
por: Isaacs, Ariel, et al.
Publicado: (2021)

Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine
por: Bartsch, Yannic C., et al.
Publicado: (2023)

Protection of calves by a prefusion-stabilized bovine RSV F vaccine
por: Zhang, Baoshan, et al.
Publicado: (2017)

The respiratory syncytial virus (RSV) prefusion F‐protein functional antibody repertoire in adult healthy donors
por: Andreano, Emanuele, et al.
Publicado: (2021)

Fusing safety and efficacy: A maternal bivalent RSV prefusion F vaccine
por: Miller, Ann M., et al.
Publicado: (2023)

1936. Efficacy of One Dose of the Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Adults ≥ 60 Years of Age Persists for 2 RSV Seasons
por: Ison, Michael G, et al.
Publicado: (2023)

Immunogenicity and protective efficacy of RSV G central conserved domain vaccine with a prefusion nanoparticle
por: Rainho-Tomko, Jennifer N., et al.
Publicado: (2022)

A human antibody potently neutralizes RSV by targeting the conserved hydrophobic region of prefusion F
por: Yi, Chunyan, et al.
Publicado: (2023)

Respiratory Syncytial Virus (RSV)
por: Walsh, Edward E., et al.
Publicado: (2015)

Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children 12–23 Months of Age
por: Díez-Domingo, Javier, et al.
Publicado: (2022)

Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B
por: Hause, Anne M., et al.
Publicado: (2017)

A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism
por: Krarup, Anders, et al.
Publicado: (2015)

Improved epitope resolution of the prefusion trimer-specific antibody AM14 bound to the RSV F glycoprotein
por: Harshbarger, Wayne, et al.
Publicado: (2021)

Emergency Department Septic Screening in Respiratory Syncytial Virus (RSV) and Non-RSV Bronchiolitis
por: Chee, Chris, et al.
Publicado: (2010)

Correction: Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B
por: Hause, Anne M., et al.
Publicado: (2017)

Is it RSV?
por: Ambrose, Christopher S.
Publicado: (2018)

Pathobiology of Respiratory Syncytial Virus (RSV)
por: Tripp, Ralph A., et al.
Publicado: (2020)

Respiratory Syncytial Virus (RSV) Update
por: Krilov, Leonard R., et al.
Publicado: (2022)

Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein
por: Gilman, Morgan S. A., et al.
Publicado: (2015)

1632. Bivalent RSV Prefusion F-Based Subunit Vaccine Generates High Neutralizing Titers in Older Adults
por: Fukushima, Yasushi, et al.
Publicado: (2023)

Effects of Formalin-Inactivated Respiratory Syncytial Virus (FI-RSV) in the Perinatal Lamb Model of RSV
por: Derscheid, Rachel J., et al.
Publicado: (2013)

Global molecular diversity of RSV – the “INFORM RSV” study
por: Langedijk, Annefleur C., et al.
Publicado: (2020)

RSV Replication, Transmission, and Disease Are Influenced by the RSV G Protein
por: Bergeron, Harrison C., et al.
Publicado: (2022)

Predictors of disease severity are similar for respiratory syncytial virus (RSV)-positive and RSV-negative induced respiratory failure
por: Davis, E, et al.
Publicado: (2004)

M Protein-Deficient Respiratory Syncytial Virus (RSV) Vaccine Protects Infant Baboons Against RSV Challenge
por: Welliver, Robert C, et al.
Publicado: (2017)

A model for respiratory syncytial virus (RSV) infection based on experimental aerosol exposure with bovine RSV in calves
por: Otto, P., et al.
Publicado: (1996)

Respiratory Syncytial Virus (RSV)–Specific Antibodies in Pregnant Women and Subsequent Risk of RSV Hospitalization in Young Infants
por: Koivisto, Karoliina, et al.
Publicado: (2021)

2657. Investigation of Respiratory Syncytial Virus (RSV) Stability in Nasal Aspirate Collected from RSV Infected Patients
por: Yamamoto, Atsuko, et al.
Publicado: (2023)

1942. Potential Public Health Impact of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Maternal Vaccine for Prevention of RSV among US Infants
por: Hanau, Ahuva, et al.
Publicado: (2023)

An outbreak of RSV infections in a neonatology clinic during the RSV-season
por: Vakrilova, Liliya, et al.
Publicado: (2021)

Eosinophil Cationic Protein and Chemokines in Nasopharyngeal Secretions of Infants with Respiratory Syncytial Virus (RSV) Bronchiolitis and Non-RSV Bronchiolitis
por: Kim, Hyun Hee, et al.
Publicado: (2007)

Transplacental transfer of maternal respiratory syncytial virus (RSV) antibody and protection against RSV disease in infants in rural Nepal()
por: Chu, Helen Y., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_kn5td5h6qc1d4h66507tgslc72